Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
114 hedge funds and large institutions have $324M invested in Paratek Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 21 reducing their positions, and 21 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 21
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
2% less funds holding
Funds holding: 116 → 114 (-2)
23% less capital invested
Capital invested by funds: $419M → $324M (-$95.5M)
44% less call options, than puts
Call options by funds: $934K | Put options by funds: $1.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$10.9M |
| 2 |
AC
Armistice Capital
New York
|
+$8.64M |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$8.25M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.28M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$14.1M |
| 2 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$12M |
| 3 |
Millennium Management
New York
|
-$3.17M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
-$2.56M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$2.26M |
PRTK Hedge Fund Activity: Q1 2018 in Review
114 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2018, worth a combined $324M — down 23% from $419M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PRTK positions and 21 closed out — a net gain of 2 holders — while 51 added to existing stakes and 21 trimmed.
The largest buyer was Highland Capital Management (Texas), adding an estimated $10.9M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $14.1M sold.
- 114 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2018, down from 116 in Q4 2017.
- Funds reported $324M of Paratek Pharmaceuticals, Inc. stock for Q1 2018, down 23% quarter-over-quarter.
- 23 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2018 and 21 closed out, a net change of +2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2018 was Highland Capital Management (Texas), an estimated $10.9M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2018 was Pictet Asset Management (UK), an estimated $14.1M sold.
Based on aggregated 13F filings for Q1 2018.